|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
gptkb:tablet
|
|
gptkbp:approvalYear
|
2023
|
|
gptkbp:approvedBy
|
gptkb:FDA
ulcerative colitis
|
|
gptkbp:ATCCode
|
L04AA57
|
|
gptkbp:brand
|
gptkb:Velsipity
|
|
gptkbp:CASNumber
|
1204669-58-8
|
|
gptkbp:category
|
immunotherapy
sphingosine-1-phosphate receptor modulator
|
|
gptkbp:chemicalFormula
|
C26H29F3N2O3S
|
|
gptkbp:developedBy
|
gptkb:Arena_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
30 hours
|
|
gptkbp:hasSMILES
|
CC(C)COC1=CC=C(C=C1)C2=NC(=C(S2)C3=CC=C(C=C3)F)C4=CC=C(C=C4)C(F)(F)F
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Etrasimod
|
|
gptkbp:indication
|
moderate to severe ulcerative colitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
S1P receptor modulator
|
|
gptkbp:molecularWeight
|
490.6 g/mol
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
gptkb:APD334
|
|
gptkbp:target
|
gptkb:sphingosine-1-phosphate_receptor_1
gptkb:sphingosine-1-phosphate_receptor_4
gptkb:sphingosine-1-phosphate_receptor_5
|
|
gptkbp:UNII
|
6Z5B6D8H8T
|
|
gptkbp:bfsParent
|
gptkb:Arena_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|